Clinical Trial Update: Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of chidamide plus regorafenib for hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Chidamide (chidamide)
• Stivarga (regorafenib)

Snippet

Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: TERMINATED